Shares of DexCom DXCM increased 1% in after-market trading after the company reported Q2 results.
Quarterly Results
Earnings per share were up 887.50% year over year to $0.79, which beat the estimate of $0.35.
Revenue of $451,800,000 rose by 34.30% year over year, which beat the estimate of $415,390,000.
Guidance
Earnings guidance hasn't been issued by the company for now.
The upcoming fiscal year's revenue expected to be between $1,850,000,000 and $1,850,000,000.
How To Listen To The Conference Call
Date: Jul 28, 2020
Time: 04:30 PM
ET Webcast URL: https://edge.media-server.com/mmc/p/e6y8exrx
Price Action
Company's 52-week high was at $446.50
52-week low: $138.28
Price action over last quarter: Up 22.44%
Company Profile
Dexcom designs and commercializes continuous glucose monitoring (CGM) systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company sells three different pieces of equipment, a sensor, a transmitter, and a receiver.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
